Indications for the use of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma
Developments in multiple myeloma - immunotherapy and personalized medicine
Conflicting results of the EMN02 and staMINA trials
Why is personalized medicine important for CLL?
Negative-data clinical trials in lymphoma presented at ASH 2015